Lewy Body Dementia Treatment Market Size (7MM) was USD 670 Million in 2022 and is projected to grow by 2034. Companies are developing therapies for treatment

Lewy Body Dementia Treatment Market Size, Drugs, Companies

Lewy Body Dementia Market Infographics

1 Key Insights
&nbsp;
2 Report Introduction
&nbsp;
3 DLB Market Overview at a Glance
&nbsp;
3.1 Market Share (%) Distribution of DLB by Therapies in 2020
&nbsp;
3.2 Market Share (%) Distribution of DLB by Therapies in 2034
&nbsp;
4 Epidemiology and Market Forecast Methodology
&nbsp;
5 Executive Summary of DLB
&nbsp;
6 Key Events
&nbsp;
7 DLB: Disease Background and Overview
&nbsp;
7.1 Introduction
&nbsp;
7.2 Classification of LBD
&nbsp;
7.3 Etiology and Risk factors
&nbsp;
7.4 Clinical Manifestations
&nbsp;
7.5 Pathophysiology
&nbsp;
7.5.1 Molecular mechanisms of Lewy body disorders
&nbsp;
7.6 Diagnosis
&nbsp;
7.6.1 Diagnostic Criteria for DLB
&nbsp;
7.6.1.1 Diagnosis and management of DLB: Fourth consensus report of the DLB consortium
&nbsp;
7.6.1.2 Diagnostic Criteria for Major Neurocognitive Disorder with Lewy Bodies (DSM-5)
&nbsp;
7.7 Management and Treatment
&nbsp;
7.7.1 Treatment Guidelines
&nbsp;
7.7.1.1 Management Guideline for Lewy body dementia (2020)
&nbsp;
7.7.1.1.1 Basic principles of LBD management
&nbsp;
7.7.1.1.2 Managing cognitive symptoms
&nbsp;
7.7.1.1.3 Managing neuropsychiatric symptoms
&nbsp;
7.7.1.1.4 Managing Parkinsonian symptoms
&nbsp;
7.7.1.1.5 Managing autonomic dysfunction
&nbsp;
7.7.1.2 Managing sleep disturbances
&nbsp;
7.7.1.3 Dementia Disease Clinical Practice Guideline 2017: The Japanese Society of Neurology
&nbsp;
7.7.1.4 Clinical Practice with Anti-dementia drugs: a Consensus Statement from British Association for Psychopharmacology
&nbsp;
7.7.1.5 Dementia: Assessment, Management and Support for People Living With Dementia and Their Carers: NICE Guideline 2018
&nbsp;
8 Epidemiology and Patient Population of DLB
&nbsp;
8.1 Key Findings
&nbsp;
8.2 Assumptions and Rationale: The 7MM
&nbsp;
8.2.1 The United States
&nbsp;
8.2.2 EU4 and the United Kingdom
&nbsp;
8.2.2.1 Germany
&nbsp;
8.2.2.2 France
&nbsp;
8.2.2.3 Italy
&nbsp;
8.2.2.4 Spain
&nbsp;
8.2.2.5 The UK
&nbsp;
8.2.3 Japan
&nbsp;
8.3 Total Prevalent cases of Dementia in the 7MM
&nbsp;
8.4 Total Diagnosed Prevalent cases of Dementia in the 7MM
&nbsp;
8.5 Total Diagnosed Prevalent cases of DLB in the 7MM
&nbsp;
8.6 The United States
&nbsp;
8.6.1 Prevalent cases of Dementia in the US
&nbsp;
8.6.2 Diagnosed Prevalent cases of Dementia in the US
&nbsp;
8.6.3 Diagnosed Prevalent cases of DLB in the US
&nbsp;
8.6.4 Gender-specific Diagnosed Prevalent cases of DLB in the US
&nbsp;
8.6.5 Age-specific Diagnosed Prevalent cases of DLB in the US
&nbsp;
8.7 EU4 and the UK
&nbsp;
8.7.1 Germany
&nbsp;
8.7.1.1&nbsp;&nbsp; Prevalent cases of Dementia in Germany
&nbsp;
8.7.1.2&nbsp;&nbsp; Diagnosed Prevalent cases of Dementia in Germany
&nbsp;
8.7.1.3&nbsp;&nbsp; Diagnosed Prevalent cases of DLB in Germany
&nbsp;
8.7.1.4&nbsp;&nbsp; Gender-specific Diagnosed Prevalent cases of DLB in Germany
&nbsp;
8.7.1.5&nbsp;&nbsp; Age-specific Diagnosed Prevalent cases of DLB in Germany
&nbsp;
8.7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France
&nbsp;
8.7.2.1 Prevalent cases of Dementia in France
&nbsp;
8.7.2.2 Diagnosed Prevalent cases of Dementia in France
&nbsp;
8.7.2.3 Diagnosed Prevalent cases of DLB in France
&nbsp;
8.7.2.4 Gender-specific Diagnosed Prevalent cases of DLB in France
&nbsp;
8.7.2.5 Age-specific Diagnosed Prevalent cases of DLB in France
&nbsp;
8.7.3 Italy
&nbsp;
8.7.3.1 Prevalent cases of Dementia in Italy
&nbsp;
8.7.3.2 Diagnosed Prevalent cases of Dementia in Italy
&nbsp;
8.7.3.3 Diagnosed Prevalent cases of DLB in Italy
&nbsp;
8.7.3.4 Gender-specific Diagnosed Prevalent cases of DLB in Italy
&nbsp;
8.7.3.5 Age-specific Diagnosed Prevalent cases of DLB in Italy
&nbsp;
8.7.4 Spain
&nbsp;
8.7.4.1 Prevalent cases of Dementia in Spain
&nbsp;
8.7.4.2 Diagnosed Prevalent cases of Dementia in Spain
&nbsp;
8.7.4.3 Diagnosed Prevalent cases of DLB in Spain
&nbsp;
8.7.4.4 Gender-specific Diagnosed Prevalent cases of DLB in Spain
&nbsp;
8.7.4.5 Age-specific Diagnosed Prevalent cases of DLB in Spain
&nbsp;
8.7.5 The UK
&nbsp;
8.7.5.1 Prevalent cases of Dementia in the UK
&nbsp;
8.7.5.2 Diagnosed Prevalent cases of Dementia in the UK
&nbsp;
8.7.5.3 Diagnosed Prevalent cases of DLB in the UK
&nbsp;
8.7.5.4 Gender-specific Diagnosed Prevalent cases of DLB in the UK
&nbsp;
8.7.5.5 Age-specific Diagnosed Prevalent cases of DLB in the UK
&nbsp;
8.8 Japan
&nbsp;
8.8.1 Prevalent cases of Dementia in Japan
&nbsp;
8.8.2 Diagnosed prevalent cases of Dementia in Japan
&nbsp;
8.8.3 Diagnosed prevalent cases of DLB in Japan
&nbsp;
8.8.4 Gender-specific Diagnosed Prevalent cases of DLB in Japan
&nbsp;
8.8.5 Age-specific Diagnosed Prevalent cases of DLB in Japan
&nbsp;
9 Patient Journey
&nbsp;
10 Emerging Drugs
&nbsp;
10.1 Key Cross Competition
&nbsp;
10.2 Neflamapimod: EIP Pharma Inc.
&nbsp;
10.2.1 Product description
&nbsp;
10.2.2 Other development activities
&nbsp;
10.2.3 Clinical development
&nbsp;
10.2.4 Clinical trial information
&nbsp;
10.2.5 Safety and efficacy
&nbsp;
10.2.6 Product profile
&nbsp;
10.2.7 Analysts&rsquo; views
&nbsp;
10.3 CT1812: Cognition Therapeutics
&nbsp;
10.3.1 Product description
&nbsp;
10.3.2 Other development activities
&nbsp;
10.3.3 Clinical development
&nbsp;
10.3.4 Clinical trial information
&nbsp;
10.3.5 Product profile
&nbsp;
10.3.6 Analysts&rsquo; views
&nbsp;
List will be continued in the report&hellip;
&nbsp;
11 DLB: Seven Major Market Analysis
&nbsp;
11.1 Key Findings
&nbsp;
11.2 Market Outlook
&nbsp;
11.3 Conjoint Analysis
&nbsp;
11.4 Key Market Forecast Assumptions
&nbsp;
11.5 Market Size of DLB in the 7MM
&nbsp;
11.6 Market Size of DLB by Therapies in the 7MM
&nbsp;
11.7 Market Size of DLB in the United States
&nbsp;
11.7.1 Total Market Size of DLB
&nbsp;
11.7.2 Market Size of DLB by Therapies
&nbsp;
11.8 Market Size of DLB in EU4 and the UK
&nbsp;
11.8.1 Germany
&nbsp;
11.8.1.1 Total Market Size of DLB
&nbsp;
11.8.1.2 Market Size of DLB by Therapies
&nbsp;
11.8.2 France
&nbsp;
11.8.2.1 Total Market Size of DLB
&nbsp;
11.8.2.2 Market Size of DLB by Therapies
&nbsp;
11.8.3 Italy
&nbsp;
11.8.3.1 Total Market Size of DLB
&nbsp;
11.8.3.2 Market Size of DLB by Therapies
&nbsp;
11.8.4 Spain
&nbsp;
11.8.4.1 Total Market Size of DLB
&nbsp;
11.8.4.2 Market Size of DLB by Therapies
&nbsp;
11.8.5 The UK
&nbsp;
11.8.5.1 Total Market Size of DLB
&nbsp;
11.8.5.2 Market Size of DLB by Therapies
&nbsp;
11.9 Market Size of DLB in Japan
&nbsp;
11.9.1 Total Market Size of DLB
&nbsp;
11.9.2 Market Size of DLB by Therapies
&nbsp;
12 Key Opinion Leaders&rsquo; View
&nbsp;
13 SWOT Analysis
&nbsp;
14 Unmet Needs
&nbsp;
15 Market Access and Reimbursement
&nbsp;
15.1 The United States
&nbsp;
15.1.1 Centre for Medicare and Medicaid Services (CMS)
&nbsp;
15.2 EU4 and the UK
&nbsp;
15.2.1 Germany
&nbsp;
15.2.2 France
&nbsp;
15.2.3 Italy
&nbsp;
15.2.4 Spain
&nbsp;
15.2.5 The United Kingdom
&nbsp;
15.3 Japan
&nbsp;
15.3.1 MHLW
&nbsp;
16 Appendix
&nbsp;
16.1 Bibliography
&nbsp;
16.2 Acronyms and Abbreviations
&nbsp;
16.3 Report Methodology
&nbsp;
17 DelveInsight Capabilities
&nbsp;
18 Disclaimer
&nbsp;
19 About DelveInsight

DelveInsight's “Dementia with Lewy Bodies (DLB) – Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the DLB, historical and forecasted epidemiology as well as the DLB market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Lewy Body Dementia Market

Lewy Body Dementia Market Insights, Epidemiology and Market Forecast – 2034

DelveInsight's Lewy Body Dementia Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Lewy Body Dementia, 